FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002809692> ?p ?o ?g. }

• W2002809692 endingPage "812" @default.
• W2002809692 startingPage "806" @default.
• W2002809692 abstract "<b>Objective:</b> To evaluate the safety and tolerability of natalizumab when added to glatiramer acetate (GA) in patients with relapsing multiple sclerosis. The primary outcome assessed whether this combination would increase the rate of development of new active lesions on cranial MRI scans vs GA alone. <b>Methods:</b> This phase 2, randomized, double-blind, placebo-controlled study included patients aged 19 to 55 years who were treated with GA for at least 1 year before randomization and experienced at least one relapse during the previous year. Patients received IV natalizumab 300 mg (n = 55) or placebo (n = 55) once every 4 weeks plus GA 20 mg subcutaneously once daily for ≤20 weeks. <b>Results:</b> The mean rate of development of new active lesions was 0.03 with combination therapy vs 0.11 with GA alone (<i>p</i> = 0.031). Combination therapy resulted in lower mean numbers of new gadolinium-enhancing lesions (0.6 vs 2.3 for GA alone, <i>p</i> = 0.020) and new/newly enlarging T2-hyperintense lesions (0.5 vs 1.3, <i>p</i> = 0.029). The incidence of infection and infusion reactions was similar in both groups; no hypersensitivity reactions were observed. One serious adverse event occurred with combination therapy (elective hip surgery). With the exception of an increase in anti-natalizumab antibodies with combination therapy, laboratory data were consistent with previous clinical studies of natalizumab alone. <b>Conclusion:</b> The combination of natalizumab and glatiramer acetate seemed safe and well tolerated during 6 months of therapy." @default.
• W2002809692 created "2016-06-24" @default.
• W2002809692 creator A5006882267 @default.
• W2002809692 creator A5007722789 @default.
• W2002809692 creator A5016495852 @default.
• W2002809692 creator A5017920520 @default.
• W2002809692 creator A5025501697 @default.
• W2002809692 creator A5057445606 @default.
• W2002809692 creator A5064778928 @default.
• W2002809692 creator A5066692631 @default.
• W2002809692 creator A5076296435 @default.
• W2002809692 creator A5077310868 @default.
• W2002809692 creator A5081342306 @default.
• W2002809692 creator A5083168810 @default.
• W2002809692 date "2009-03-02" @default.
• W2002809692 modified "2023-10-16" @default.
• W2002809692 title "GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study" @default.
• W2002809692 cites W1514064771 @default.
• W2002809692 cites W1978838993 @default.
• W2002809692 cites W2005506388 @default.
• W2002809692 cites W2006236475 @default.
• W2002809692 cites W2019582599 @default.
• W2002809692 cites W2035445993 @default.
• W2002809692 cites W2057903396 @default.
• W2002809692 cites W2066124230 @default.
• W2002809692 cites W2072966534 @default.
• W2002809692 cites W2085937163 @default.
• W2002809692 cites W2087589796 @default.
• W2002809692 cites W2094772849 @default.
• W2002809692 cites W2103758700 @default.
• W2002809692 cites W2105490558 @default.
• W2002809692 cites W2106467284 @default.
• W2002809692 cites W2108617074 @default.
• W2002809692 cites W2112165124 @default.
• W2002809692 cites W2139367012 @default.
• W2002809692 cites W2159061752 @default.
• W2002809692 cites W2169098250 @default.
• W2002809692 cites W2171907184 @default.
• W2002809692 doi "https://doi.org/10.1212/01.wnl.0000343880.13764.69" @default.
• W2002809692 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2821836" @default.
• W2002809692 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19255407" @default.
• W2002809692 hasPublicationYear "2009" @default.
• W2002809692 type Work @default.
• W2002809692 sameAs 2002809692 @default.
• W2002809692 citedByCount "120" @default.
• W2002809692 countsByYear W20028096922012 @default.
• W2002809692 countsByYear W20028096922013 @default.
• W2002809692 countsByYear W20028096922014 @default.
• W2002809692 countsByYear W20028096922015 @default.
• W2002809692 countsByYear W20028096922016 @default.
• W2002809692 countsByYear W20028096922017 @default.
• W2002809692 countsByYear W20028096922018 @default.
• W2002809692 countsByYear W20028096922019 @default.
• W2002809692 countsByYear W20028096922020 @default.
• W2002809692 countsByYear W20028096922021 @default.
• W2002809692 countsByYear W20028096922023 @default.
• W2002809692 crossrefType "journal-article" @default.
• W2002809692 hasAuthorship W2002809692A5006882267 @default.
• W2002809692 hasAuthorship W2002809692A5007722789 @default.
• W2002809692 hasAuthorship W2002809692A5016495852 @default.
• W2002809692 hasAuthorship W2002809692A5017920520 @default.
• W2002809692 hasAuthorship W2002809692A5025501697 @default.
• W2002809692 hasAuthorship W2002809692A5057445606 @default.
• W2002809692 hasAuthorship W2002809692A5064778928 @default.
• W2002809692 hasAuthorship W2002809692A5066692631 @default.
• W2002809692 hasAuthorship W2002809692A5076296435 @default.
• W2002809692 hasAuthorship W2002809692A5077310868 @default.
• W2002809692 hasAuthorship W2002809692A5081342306 @default.
• W2002809692 hasAuthorship W2002809692A5083168810 @default.
• W2002809692 hasBestOaLocation W20028096922 @default.
• W2002809692 hasConcept C126322002 @default.
• W2002809692 hasConcept C141071460 @default.
• W2002809692 hasConcept C142724271 @default.
• W2002809692 hasConcept C168563851 @default.
• W2002809692 hasConcept C197934379 @default.
• W2002809692 hasConcept C203014093 @default.
• W2002809692 hasConcept C204243189 @default.
• W2002809692 hasConcept C204787440 @default.
• W2002809692 hasConcept C27081682 @default.
• W2002809692 hasConcept C2778375690 @default.
• W2002809692 hasConcept C2778577042 @default.
• W2002809692 hasConcept C2780640218 @default.
• W2002809692 hasConcept C2781004633 @default.
• W2002809692 hasConcept C71924100 @default.
• W2002809692 hasConcept C90924648 @default.
• W2002809692 hasConceptScore W2002809692C126322002 @default.
• W2002809692 hasConceptScore W2002809692C141071460 @default.
• W2002809692 hasConceptScore W2002809692C142724271 @default.
• W2002809692 hasConceptScore W2002809692C168563851 @default.
• W2002809692 hasConceptScore W2002809692C197934379 @default.
• W2002809692 hasConceptScore W2002809692C203014093 @default.
• W2002809692 hasConceptScore W2002809692C204243189 @default.
• W2002809692 hasConceptScore W2002809692C204787440 @default.
• W2002809692 hasConceptScore W2002809692C27081682 @default.
• W2002809692 hasConceptScore W2002809692C2778375690 @default.
• W2002809692 hasConceptScore W2002809692C2778577042 @default.
• W2002809692 hasConceptScore W2002809692C2780640218 @default.
• W2002809692 hasConceptScore W2002809692C2781004633 @default.

• next